Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer’s disease: a focused review on recent advances
Joyce R. Chong(National University of Singapore), Mitchell K.P. Lai(National University of Singapore), Kaj Blennow(Sahlgrenska University Hospital), Tomotaka Tanaka(Kyoto University), Nicholas J. Ashton(King's College London), Michael Schöll(Wallenberg Wood Science Center), Henrik Zetterberg(University of Wisconsin–Madison), Thomas K. Karikari(University of Pittsburgh), Christopher Chen(National University of Singapore)
Cited by 111
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k